IN 006 - InnoRNA
Alternative Names: Bivalent RSV vaccine - InnoRNA; IN-006 - InnoRNALatest Information Update: 12 Mar 2024
At a glance
- Originator InnoRNA
- Class Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 06 Mar 2024 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (IM) (InnoRNA Pipeline, February 2024)
- 06 Mar 2024 The US FDA approves IND application for IN 006 in Respiratory syncytial virus (Prevention)
- 01 Mar 2024 Shenzhen Shenxin Biotechnology plans a phase I trial for Respiratory syncytial virus infections (Prevention) in USA (IM) in August 2024 (NCT06287450)